Humana Rating Increased to Buy at Stifel (HUM)
Humana (NYSE:HUM) was upgraded by Stifel from a “hold” rating to a “buy” rating in a research note issued on Friday. The firm currently has a $155.00 price objective on the stock. Stifel’s price objective suggests a potential upside of 24.65% from the company’s current price.
Humana (NYSE:HUM) opened at 124.35 on Friday. Humana has a 52-week low of $79.82 and a 52-week high of $126.44. The stock’s 50-day moving average is $117.0 and its 200-day moving average is $107.5. The company has a market cap of $19.247 billion and a P/E ratio of 17.61.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, May 7th. The company reported $2.35 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.94 by $0.41. During the same quarter last year, the company posted $2.69 earnings per share. Analysts expect that Humana will post $7.80 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, July 25th. Shareholders of record on Monday, June 30th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date of this dividend is Thursday, June 26th. This is a positive change from Humana’s previous quarterly dividend of $0.27.
Other equities research analysts have also recently issued reports about the stock. Analysts at Leerink Swann reiterated an “outperform” rating on shares of Humana in a research note on Friday, May 23rd. They now have a $140.00 price target on the stock, up previously from $135.00. Separately, analysts at Argus raised their price target on shares of Humana from $125.00 to $135.00 in a research note on Thursday, May 22nd. They now have a “buy” rating on the stock. Finally, analysts at Deutsche Bank raised their price target on shares of Humana from $95.00 to $100.00 in a research note on Monday, May 12th. They now have a “sell” rating on the stock. Three equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $122.15.
Humana Inc (NYSE:HUM) is a health care company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.